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Purpose: Sunitinib malate (Sutent; Pfizer, New York, NY, USA) is a highly selective 
multi-targeted agent and has been reported to have potent anti-tumor effects against 
various tumors, including renal cell carcinoma and gastrointestinal stromal tumors. 
In this study, we explored in vitro the anti-tumor effect and related molecular mecha-
nisms of sunitinib malate against human bladder cancer cell lines. We also determined 
the synergistic anti-tumor effect between sunitinib and conventional cytotoxic drugs, 
cisplatin and gemcitabine, in bladder cancer cells.
Materials and Methods: Six human cancer cell lines (HTB5, HTB9, T24, UMUC14, 
SW1710, and J82) were exposed to an escalating dose of sunitinib alone or in combina-
tion with cisplatin/gemcitabine, and the cytotoxic effect of the drugs was examined by 
CCK-8 assay. The synergistic effect between sunitinib and cisplatin/gemcitabine was 
determined by the combination index (CI) and clonogenic assay. Alterations in cell cycle 
(cyclin D, B1), survival (p-Akt, t-Akt), and apoptosis (Bax, Bad) regulator expression 
were analyzed by Western blotting.
Results: Like cisplatin and gemcitabine, sunitinib exerted a dose- and time-dependent 
anti-tumor effect in bladder cancer cells. However, sunitinib exhibited entirely differ-
ent sensitivity profiles from cisplatin and gemcitabine. Sunitinib suppressed the ex-
pression of cyclin B1, p-Akt, and t-Akt while augmenting the expression of cyclin D and 
pro-apoptotic Bax and Bad in HTB5 cells. Analysis of the drug combination by the iso-
bolic method and clonogenic assay revealed that sunitinib acts in synergy with gemcita-
bine in HTB5 cells.
Conclusions: These results indicate that sunitinib malate has a potent anti-tumor effect 
and may synergistically enhance the anti-tumor effect of gemcitabine in human bladder 
cancer cells.
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INTRODUCTION
Although most bladder cancer patients present with super-
ficial disease, approximately 70% of cases experience dis-
ease recurrence and 10% to 20% experience progression to 
invasive disease. Even though bladder transitional cell 
carcinoma is relatively chemotherapy-sensitive, the re-
sponses are usually transient and most responding dis-
eases recur within the first year, with median survival 
ranging from 12 to 14 months. Thus, during the past few 
decades, numerous trials have been conducted to develop 
new treatment regimens for advanced bladder cancer [1-4].
Sunitinib malate (Sutent; Pfizer, New York, NY, USA) 
is a multi-targeted receptor tyrosine kinase inhibitor that 
acts on vascular endothelial growth factor (VEGF) receptor 
1, 2, and 3; platelet-derived growth factor (PDGF) receptor; 
stem cell receptor (KIT); and FMS-like tyrosine kinase-3 
receptor (FLT3), and its anti-tumor activity has been dem-Korean J Urol 2011;52:55-63
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onstrated in various tumors, including renal cell carcino-
ma (RCC), gastrointestinal stromal tumor, non-small-cell 
lung cancer, and colorectal cancer [5-9].
The anti-tumor effect of sunitinib malate in RCC is tight-
ly related to the VEGF/PDGF signaling axis, distal effec-
tors of the von Hippel-Lindau tumor suppressor. Sunitinib 
malate exerts its anti-angiogenic and pro-apoptotic effect 
in RCC through the suppression of this axis signaling. 
According to this knowledge, in the present study we exam-
ined in vitro the anti-tumor effect and related mechanisms 
of sunitinib malate in human bladder cancer cells, one of 
the hypervascular tumors with high VEGF expression 
[10-14]. We also explored the synergistic anti-tumor effect 
between sunitinib malate and conventional cytotoxic che-
motherapy agents, gemcitabine and cisplatin, in bladder 
cancer cells.
MATERIALS AND METHODS
1. Cell lines and chemicals
Bladder cancer cell lines (HTB5, HTB9, T24, UMUC14, 
SW1710, and J82) were purchased from the ATCC 
(Manassas, VA, USA) and were maintained in RPMI (T24), 
DMEM (SW1710, UMUC14, SW1710, J82), and MEM 
(HTB5) supplemented with 10% fetal bovine serum 
(Mediatech, Herndon, VA, USA) and 100 U/ml penicillin 
and 100 mg/l streptomycin (Gibco BRL, Grand Island, NY, 
USA). Sunitinib malate and cisplatin were obtained from 
Pfizer (Pfizer Korea LTD., Seoul, Korea) and gemcitabine 
was obtained from Lilly (Lilly Korea LTD., Seoul, Korea).
2. Analysis of in vitro anti-tumor effect
The CCK-8 assay was used to determine the anti-tumor ef-
fect of each drug. Briefly, cells in 96-well plates were treat-
ed with escalating doses of sunitinib malate (0.313-20 μM), 
cisplatin (0.039-40.0 μg/ml), or gemcitabine (0.313-10.0 
μM) for 24, 48, and 72 hours and then 10 μl of CCK-8 sol-
ution (Cell counting kit-8, Dojindo Molecular Technolo-
gies, Inc. Gaithersburg, MD, USA) was added to 100 μl of 
media in each well and absorbance was determined at 450 
nm after 4 hours of incubation.
3. Determination of synergistic anti-tumor effect between 
sunitinib malate and cisplatin/gemcitabine
HTB5 cells were exposed to sunitinib malate alone or si-
multaneously with cisplatin or gemcitabine and the syner-
gistic effect between the two drugs was determined by the 
combination index (CI) by use of the Chou and Talalay 
method as described previously [15]. The CI indicates a 
synergistic effect when ＜1.0, an antagonistic effect when 
＞1.0, and an additive effect when equal to 1.0.
4. Colony-forming assay
For the clonogenic assay, 2x10
3 HTB5 cells were plated in 
6 cm culture discs and treated with increasing doses of suni-
tinib malate (5 μM, 10 μM, and 20 μM) for 48 hours. The 
drug was then washed out with PBS and the cells were 
maintained for another 10 days before visualization of colo-
nies formed with 0.4% crystal violet staining. Only colonies 
larger than 0.2 mm in diameter were counted for quantita-
tive analysis.
5. Analysis of cell cycle- and survival-related protein ex-
pression
HTB5 cells exposed to a graded concentration of sunitinib 
malate (5 μM, 10 μM, and 20 μM) for 48 hours were har-
vested and incubated for 15 to 20 min in 200 μl of RIPA lysis 
buffer containing IGEPAL CA630, sodium lauryl sulphate, 
sodium chloride, Tris-EDTA, deoxycholic acid, and pro-
tease inhibitor cocktail (Thermos Scientific, Rockford, IL, 
USA). Thirty micrograms of protein was fractionated by 
SDS-PAGE and transferred to polyvinylidene difluoride 
(PVDF) membranes (Millipore, Billerica, MA, USA). After 
blocking with TBST containing 5% milk for 1 hour, the 
membranes were incubated overnight at 4ºC with the re-
spective primary antibody [cyclin D, cyclin B1, phos-
pho-Akt (p-Akt), and total-Akt (t-Akt) from Cell Signaling 
Technology, Danvers, MA, USA, and Bax and Bad from 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA]. The 
membranes were then incubated with secondary anti-
bodies and protein expression was detected with an en-
hanced chemiluminescence Western blot substrate kit 
(Pierce, Rockford, IL, USA).
6. Statistical analysis
Unless specified, the results were expressed as the 
Mean±SD of the data collected from at least three in-
dependent experiments. Statistical significance was de-
termined by the two-sample t-test and p-values ＜0.05 and 
0.01 were considered as significant.
RESULTS
1. Anti-tumor effect of sunitinib malate on human bladder 
cancer cells
Sunitinib malate showed a dose- and time-dependent an-
ti-tumor effect in all cell lines tested except J82, in which 
it exerted dose-dependent but not time-dependent activity 
(Fig. 1). In the concentration range of 10 μM or higher, a 
72-hour exposure to sunitinib malate suppressed the pro-
liferation of HTB5 (82.8±9.4%), HTB9 (74.9±28.2%), 
UMU14 (72.3±4.5%), and SW1710 (80.5±6.8%) cells up to 
70% or higher, whereas T24 (32.9±7.6%) and J82 (28.7± 
0.7%) showed only partial responses to sunitinib treatment 
(Fig. 1). All cell lines were also exposed to graded doses of 
cisplatin (0.039-40.0 μg/ml) or gemcitabine (0.313-10.0 
μM) for 48 to 72 hours to determine the sensitivity to each 
drug, and the results are summarized in Table 1. Compared 
with moderately differentiated HTB9 cells (grade 2), for 
which the IC50 values for 48-hour and 72-hour exposure 
were 5.23±1.0 μM and 2.31±0.95 μM, respectively, all other 
poorly differentiated cell lines (grades 3, 4) demonstrated 
relatively higher resistance to sunitinib (IC50 5.34±0.67 μM 
to 11.89±1.34 μM) depending on the exposure time. HTB9 Korean J Urol 2011;52:55-63
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FIG. 1. Dose- and time-dependent anti-tumor effect of sunitinib malate in human bladder cancer cell lines. Six human bladder 
transitional cell carcinoma cell lines of various differentiation (HTB5 - grader 4; HTB9 - grade 2; T24 - grade 3; UMUC14 - grade 4;
SW1710 - grade 3; and J82 - grade 3) were exposed to escalating doses of sunitinib malate (0.313-20 μM) for 24, 48, and 72 hours and
the anti-tumor effect in each cell line was determined by CCK-8 assay. Each data point represents the Mean±SD of at least three 
independent experiments.
cells showed moderate sensitivity to either cisplatin or 
gemcitabine (IC50 values for cisplatin and gemcitabine at 
72 hours were 0.71±0.13 μg/ml and 1.1±0.22 μM, re-
spectively). Poorly differentiated HTB5 (grade 4) and T24 
(grade 3) cells showed the highest sensitivity to cisplatin 
(IC50 0.41±0.6 to 1.33±0.7 μg/ml), but exhibited relatively 
lower sensitivity to either sunitinib (IC50 4.05±0.91 to 
9.86±1.75) or gemcitabine (IC50 9.59±8.7 to 142.49± 112.02 
μM).Korean J Urol 2011;52:55-63
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TABLE 1. IC50 and relative resistance of bladder cancer cell lines
Cell line
48 h 72 h
IC50 (SD)
Relative
resistance
IC50 (SD)
Relative 
resistance
Sunitinib (μM)
HTB9
HTB5
T24
UMUC14
SW1710
J82
Cisplatin (μg/ml)
HTB9
HTB5
T24
UMUC14
SW1710
J82
Gemcitabine (μM)
HTB9
HTB5
T24
UMUC14
SW1710
J82
  5.23 (1.00)
  7.13 (1.59)
  9.93 (0.97)
  5.34 (0.67)
10.57 (1.79)
14.29 (3.31)
  1.69 (0.81)
  0.82 (0.19)
  1.33 (0.47)
  1.83 (0.17)
  2.19 (0.56)
  4.98 (2.01)
    1.3 (0.25)
  142.49 (112.02)
12.55 (9.17)
    0.3 (0.02)
  0.41 (0.13)
  8.29 (3.18)
1
   1.3
   1.9
   1.0
   2.0
   2.7
1
   0.4
   0.7
   1.1
   1.3
   2.9
1
109.6
   9.7
   0.2
   0.3
   6.4
  2.31 (0.95)
  4.05 (0.91)
  9.86 (1.75)
  4.69 (0.59)
  3.51 (0.55)
11.89 (1.34)
  0.71 (0.13)
  0.41 (0.18)
  0.46 (0.11)
  0.89 (0.21)
  1.28 (0.57)
  0.77 (0.31)
    1.1 (0.22)
111.89 (88.54)
  9.59 (5.11)
    0.1 (0.03)
  0.27 (0.09)
  6.59 (1.45)
1
   1.6
   4.2
   2.0
   1.5
   5.1
1
   0.6
   0.6
   1.3
   1.8
   1.1
1
101.7
   8.7
   0.1
   0.2
   5.9
IC50:  inhibitory concentration 50, SD: standard deviation
FIG. 2. Analysis of of cell cycle and survival regulatory protein expression in the HTB5 cell line. (A) HTB5 cells were exposed to 
increasing doses of sunitinib malate (5.0 μM, 10.0 μM, and 20.0 μM) for 72 hours and cyclin D, cyclin B1, p-Akt, t-Akt, Bax, and Bad
expression was determined by Western blotting. (B) p-Akt and t-Akt expression was measured by densitometric method and 
percentile changes from untreated control were analyzed. Each data point represents the Mean±SD of two independent experiments. 
(
a and 
b: p＜0.05, respectively; control vs. each treatment).
2. Sunitinib-induced alterations of cell cycle and survival 
regulator expression
Exposure to sunitinib caused a decreased expression of cy-
clin B1 in HTB5 cells, whereas cyclin D expression in-
creased (Fig. 2). Sunitinib treatment significantly sup-
pressed both p-Akt (p＜0.05) and t-Akt (p＜0.01) ex-
pression in HTB5 cells and also caused an increase in the 
expression of the pro-apoptotic Bax and Bad (Fig. 2).
3. Synergistic anti-tumor effect between sunitinib and 
gemcitabine against bladder cancer cells
To test the synergistic anti-tumor effect, poorly differ-
entiated HTB5 cells were exposed to sunitinib alone or in 
combination with gemcitabine. Over a wide range of con-
centrations, sunitinib exerted a dose-dependent anti-tu-
mor effect and its combination with gemcitabine yielded a 
significantly greater anti-tumor effect than that of either 
agent alone (Fig. 3). These results were also confirmed by Korean J Urol 2011;52:55-63
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FIG. 3. Combination treatment of human bladder cancer cells with sunitinib malate. To check the synergistic anti-tumor effect 
between sunitinib malate and a conventional chemotherapy agent, the HTB5 cell line was exposed to increasing doses of sunitinib 
malate alone or in combination with gemcitabine (A) or cisplatin (B) at a fixed ratio (1:1) for 48 hours and the anti-tumor effect was
analyzed by CCK-8 assay. The median-effect plot (C) and the dose-effect plot (E) of the sunitinib and gemcitabine combination showed
a synergistic anti-tumor effect for the mid-range of dose combinations, whereas the sunitinib and cisplatin combination (D, F) showed 
no significant synergistic effect over the whole-dose combinations tested.
the clonogenic assay in which combination treatment of 
HTB5 cells with sunitinib and gemcitabine showed sig-
nificantly higher suppression of colony formation (4.5± 
2.9% of untreated control) than single treatment with ei-
ther 2.5 μM of sunitinib malate (85.3±1.31% of untreated 
control, p=0.005) or 0.625 μM of gemcitabine (88.1±13.6% 
of control, p=0.001) (Fig. 4). Because the sunitinib and gem-
citabine combination indicated synergism, we performed 
a fixed ratio (1 to 1) combination treatment of HTB5 cells 
to determine the combination index. These results are Korean J Urol 2011;52:55-63
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FIG. 4. Colony formation of sunitinib-treated HTB5 cells. Two thousand HTB5 cells were seeded in 6 cm culture plates and permitted
to attach overnight. After 48 hours of single or combination treatment with sunitinib malate and cisplatin, cells were washed with
PBS and cultured in drug-free media for an additional 7 days before crystal violet staining. Only the number of colonies having a diameter
of 0.2 mm or larger were counted for analysis. Changes in colony formation in with sunitinib malate ((B) 1.25 μM, (C) 2.5 μM, (D) 5.0
μM) or cisplatin ((E) 0.625 μg/ml) single treatment or combination treatment ((F) 2.5 μM of sunitinib malate plus 0.625 μg/ml of cisplatin)
from untreated control (A) are expressed as percentages. Each data point represents the Mean±SD of duplicated experiments.
TABLE 2. Parameters related with dose-effect responses of 
sunitinib malate and gemcitabine in HTB5 bladder cancer cells
  Compound m
a Dm (μM)
b r
c
Sunitinib 1.05532     6.08988 0.89844
Gemcitabine 0.35456 198.63541 0.91838
Sunitinib＋  0.79855     4.52277 0.93821
  Gemcitabine
a: coefficient signifying the shape of the dose-effect curve, 
b: dose 
of drugs required to inhibit 50% of cell proliferation, 
c: correlation
coefficient signifying conformity of the data to the mass-action
law.
summarized in Table 2 and 3. The median effect doses 
(Dm=IC50) for sunitinib, gemcitabine, and their combina-
tion were 6.089 μM, 198.635 μM, and 4.522 μM, re-
spectively, indicating a more effective anti-tumor effect of 
the combination than of either agent alone. The median ef-
fect analysis showed CIs＜1 between fa=0.15 and 0.7, 
which suggests a synergistic anti-tumor effect between the 
two drugs across the broad range of fraction affected (15- 
70% cell death) (Fig. 5). The dose-reduction index (DRI) al-
so showed that the sunitinib and gemcitabine combination 
produced favorable dose reduction along the wide fa range 
(Table 3).
No detectible synergistic anti-tumor effect was shown 
when HTB5 cells were treated with sunitinib together with 
cisplatin.
DISCUSSION
Sunitinib malate is a small molecular multi-targeted ty-
rosine kinase inhibitor that directly inhibits VEGFR, 
PDGFR, KIT, and FLT3. The main anti-tumor mechanism 
of sunitinib malate is through its inhibition of angiogenesis 
and the induction of tumor apoptosis by inhibiting tyrosine 
kinases expressed by cancer. It is well reported that the 
VEGF level is highly correlated with the clinical output of 
well vascularized tumors such as RCC and GIST, and on 
the basis of the results of clinical trials, the use of sunitinib 
malate for patients with advanced RCC hRCCand gastro-
intestinal stromal tumor was approved by the Food and 
Drug Administration.
High serum VEGF levels are associated with high blad-Korean J Urol 2011;52:55-63
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TABLE 3. Dose-effect relationships of sunitinib malateand gemcitabine in HTB5 cell lines at 72 hours of exposure
Sunitinib (μM) Gemcitabine (μM) Fraction affected (fa) Combination index (CI) Dose reduction index (DRI)
0.7593
1.6372
2.7285
4.1471
6.0899
8.9427
13.5924
22.6520
48.8458
0.4043
3.9812
18.2061
63.3009
198.6354
623.3094
2,167.1890
9,910.6937
9.759e＋004
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
2.630
2.054
1.743
1.524
1.346
1.190
1.040
0.883
0.689
1.400
4.995
11.631
23.255
43.919
82.944
165.839
386.152
1,377.291
Combination (sunitinib:gemcitabine=1:1)
0.28869
0.79701
1.56530
2.72202
4.52277
7.51481
13.06803
25.66523
70.85528
0.28869
0.79701
1.56530
2.72202
4.52277
7.51481
13.06803
25.66523
70.85528
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.094
0.687
0.660
0.699
0.765
0.852
0.967
1.136
1.451
FIG. 5. fa-combination index (CI) plot of sunitinib malate combination treatment. HTB5 cells were treated with escalating concentrations
of gemcitabine (A) or cisplatin (B) either alone or in combination with sunitinib at a 1:1 fixed ratio for 48 hours and the CI was calculated
by using the Chou and Talalay equation as described previously. On the basis of the CI values at each fraction affected (fa), the fa-CI
plot was generated in which CI＜1, CI=1, and CI＞1 denote synergism, additivity, and antagonism, respectively.
der cancer stage, grade, vascular invasion, and metasta-
ses. Also, high VEGF mRNA expression in superficial blad-
der cancer is related to early tumor recurrence and pro-
gression to a more invasive phenotype [10,16-19]. These 
findings suggest the possible anti-tumor and anti-angio-
genic effect of sunitinib malate in advanced bladder cancer. 
However, only a few sunitinib malate clinical trials for 
bladder cancer have been performed recently, with mixed Korean J Urol 2011;52:55-63
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initial results, and there have been only a few in vitro or 
in vivo studies of the anti-tumor effect and related mecha-
nisms of sunitinib malate in bladder cancer [10,20,21].
In this study, we explored in vitro the anti-tumor effect 
of sunitinib malate on human bladder cancer cell lines of 
various differentiation and analyzed the results compared 
with the conventional chemotherapeutic agents cisplatin 
and gemcitabine. All three drugs exhibited a dose- and 
time-dependent anti-tumor effect against bladder cancer 
cells. However, the sensitivity spectra of the drugs differed 
according to the bladder cancer cell lines tested. For exam-
ple, UMUC14 cells (grade 4) showed relatively fair sensi-
tivity to all three drugs (IC50 4.69±0.59 μM for sunitinib ma-
late, 0.89±0.21 μg/ml for cisplatin, and 0.1±0.03 μM for 
gemcitabine with 72 hours of exposure), whereas HTB5 
(grade 4) exhibited high sensitivity only to cisplatin treat-
ment (IC50 0.41±0.6 μg/ml), exhibiting moderate and ex-
tremely low sensitivity to sunitinib malate (IC50 4.05±1.6 
μM with 72 hours of exposure) and gemcitabine (111.89± 
88.54 μM with 72 hours of exposure), respectively. These 
results show that the sensitivities of bladder cancer cell 
lines to sunitinib might be regulated by factors different 
from those determining sensitivity to cisplatin or gemci-
tabine. In other words, it is possible that sunitinib malate 
could be used as a first- or second-line therapy in selected 
patients with advanced bladder cancer regardless of the re-
sponse to cisplatin- or gemcitabine-based chemotherapy.
　In our study, exposure of HTB5 cells to sunitinib malate 
resulted in a marked suppression of cyclin B1 expression 
accompanied by increased expression of cyclin D. Sunitinib 
malate also suppressed the expression of p-Akt and t-Akt. 
These findings indicate that the anti-tumor mechanism of 
sunitinib malate in bladder cancer is at least partly through 
G2 phase cell cycle arrest and suppression of the Akt sur-
vival pathway. The sunitinib-mediated augmentation of 
pro-apoptotic Bax and Bad expression suggests the possi-
ble involvement of the mitochondrial apoptotic pathway in 
the anti-tumor action of sunitinib malate against bladder 
cancer cells.
In tumors such as RCC, testicular germ cell tumors, 
breast cancer, and pancreatic cancer, sunitinib malate has 
been reported to have synergistic anti-tumor activity with 
various treatment modalities, including targeted agents, 
chemotherapy drugs, and even radiation therapy [22-28]. 
However, studies of the synergistic anti-tumor effect be-
tween sunitinib malate and conventional cytotoxic agents 
in bladder cancer are very rare. Because cisplatin and gem-
citabine are the active drugs and mainstay of chemotherapy 
regimens for advanced bladder cancer, in this study we an-
alyzed the synergistic anti-tumor effect between sunitinib 
malate and these two drugs. Concomitant treatment of 
HTB5 cells with sunitinib malate and gemcitabine signi-
ficantly enhanced the anti-tumor effect of both drugs along 
the fa value between 0.15 to 07, indicating the optimal syn-
ergistic anti-tumor effect between the two drugs at the 
mid-range of combination doses. The clonogenic assay also 
demonstrated compatible results. Although sunitinib ma-
late as a single agent caused dose-dependent suppression 
of colony formation of HTB5 cells, the overall decrease in 
clonogenicity was significantly greater when HTB5 cells 
were exposed to sunitinib malate and gemcitabine simul-
taneously. Although combination of high-dose- range suni-
tinib malate and cisplatin showed a mild additive anti-tu-
mor effect (CI=1.23), over a wide range of dose combina-
tions, no significant synergistic enhancement in anti-tu-
mor effect between sunitinib malate and gemcitabine 
against HTB5 was shown. These results are compatible 
with those obtained by Sonpavde et al, in which sunitinib 
malate and cisplatin showed a synergistic anti-tumor ef-
fect against human bladder cancer cell lines only in high- 
dose combinations [29].
In summary, our findings suggest a synergistic anti-tu-
mor effect between sunitinib malate and gemcitabine in 
bladder cancer cells, providing a rationale for the develop-
ment of a sunitinib-based combination therapy regimen 
with a conventional chemotherapy agent such as gemcita-
bine for advanced bladder cancer.
CONCLUSIONS
In the present study, sunitinib malate showed dose- and 
time-dependent anti-tumor activity against human blad-
der cancer cell lines of various differentiations. The sensi-
tivity profile of sunitinib malate differed from the profiles 
identified for cisplatin and gemcitabine, indicating that no 
cross-sensitivity or resistance exists between sunitinib 
malate and cisplatin/gemcitabine. Also, the combination 
treatment of sunitinib malate and gemcitabine was superi-
or to either agent as a single treatment regarding anti-tu-
mor potential. These findings suggest the possibility of 
clinical application of sunitinib-based single targeted ther-
apy or combination treatment with conventional cytotoxic 
chemotherapy drugs for advanced bladder cancer. Consi-
dering the extremely poor prognosis of patients with ad-
vanced bladder cancers, the development of sunitinib- 
based novel treatment regimens is of utmost clinical im-
portance. Because the IC50 of sunitinib malate in vitro is 
reported to be significantly higher than the low nanomolar 
free and active drug concentrations obtained in vivo, fur-
ther studies are needed to confirm the synergistic anti-tu-
mor effect of sunitinib-based combination treatment in 
vivo [29].
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